Sara Mangsbo

Uppsala University

sara.mangsbo@uu.se

Keywords

antibody therapeutics, Biopharmaceuticals, Cancer, immuno-oncology, Immunology, Immunotoxicity, Oncology, Pharmacology

Key Publications

EAK Fletcher, W van Maren, R Cordfunke, J Dinkelaar, JDC Codee, G van der Marel, CJM Melief, F Ossendorp, JW Drijfhout, SM Mangsbo. Formation of immune-complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently-linked peptides in an ex-vivo blood loop system. J Immunol. 2018 Jul 1;201(1):87-97018

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW. Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Mol Immunol. 2018 Jan;93:115-124

Fletcher EAK, Eltahir M, Lindqvist F, Rieth J, Törnqvist G, Leja-Jarblad J, Mangsbo SM. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics. Int Immunopharmacol. 2018 Jan;54:1-11.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM. Locally delivered check-point blockade prevents growth of experimental bladder cancer. Eur J Immunol. 2016 Nov 22.

Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity. Clin Cancer Res. 2014

SciLifeLab / Contact / Sara Mangsbo

Tumor Immunology and Targeted Therapeutics

Our research group investigates the dynamic interplay between tumors and the immune system throughout cancer progression. We aim to uncover fundamental mechanisms that shape disease stages and influence therapeutic outcomes.

Research Themes

Tumor-Immune System Interactions: We study how immune responses evolve during tumor growth and progression, identifying key checkpoints and drivers of immune escape.

Mechanisms of Tumor Invasiveness: Understanding the molecular and cellular factors that promote aggressive tumor behavior.

Targeted Drug Delivery: We design innovative delivery systems for peptide- and oligonucleotide-based drugs, enabling precision targeting to diseased tissues.

Innovation, the ADAC Technology: We have developed the Adaptable Drug Affinity Conjugate (ADAC) platform, a versatile strategy that integrates targeted drug delivery with precision medicine. ADAC enables the fusion of therapeutic payloads with disease-specific targeting, opening new avenues for personalized cancer treatment.

Our Vision: By combining mechanistic insights with cutting-edge drug delivery technologies, we strive to develop therapies that are more effective, safer, and tailored to individual patients.

Group members

Solène Beauvois
Ted Ebendal
Alexandros Kostakis
Maria Lampinen
Martin Lord
Polat Turker
Rosanne Veerman
Oskar Wiggins